Project Description
Trastuzumab has been used in clinical settings to block the HER2/neu activity. This postdoctoral application focused on EGCG and other green tea polyphenols as sensitizers and as effective agents in HER2/neu-resistant breast cancer cells. A mechanistic insight of their effcacy was sought by examination of the EGFR-mediated signalling pathways.